Cargando…

Protease inhibitors for the treatment of hepatitis C virus infection

The hepatitis C virus (HCV) has affected an estimate of 80 million individuals worldwide and is a strain of public health. Around 25–30% of patients in Europe and the US infected with HIV are coinfected with HCV. Despite treatment modalities containing a NS3/4A protease inhibitor in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Leuw, Philipp, Stephan, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	German Medical Science GMS Publishing House 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301719/ https://www.ncbi.nlm.nih.gov/pubmed/30671330 http://dx.doi.org/10.3205/id000034

Ejemplares similares

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
por: Gentile, Ivan, et al.
Publicado: (2014)

The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
por: Kwo, Paul Y., et al.
Publicado: (2011)

Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
por: Zeminian, Luciana Bonome, et al.
Publicado: (2013)

Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus
por: Abian, Olga, et al.
Publicado: (2013)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
por: Rong, Libin, et al.
Publicado: (2013)

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
por: Jensen, Sanne Brun, et al.
Publicado: (2019)

Hepatitis C Virus Protease Inhibitors Suppress Virus Replication and Act Synergistically with the SARS-CoV2 Polymerase Inhibitor Remdesivir
por: Bafna, Khushboo, et al.
Publicado: (2021)

Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2022)

Molecular models of NS3 protease variants of the Hepatitis C virus
por: da Silveira, Nelson JF, et al.
Publicado: (2005)

Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
por: Chatel-Chaix, Laurent, et al.
Publicado: (2010)

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection
por: Sherman, Kenneth E, et al.
Publicado: (2017)

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
por: Gammeltoft, Karen A., et al.
Publicado: (2021)

The Ubiquitin-Specific Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity
por: Li, Yujia, et al.
Publicado: (2019)

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
por: Romano, Keith P., et al.
Publicado: (2012)

Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation
por: Lim, Yun-Sook, et al.
Publicado: (2021)

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study
por: Callefi, Luciana Azevedo, et al.
Publicado: (2017)

X Protein of Hepatitis B Virus Resembles a Serine Protease Inhibitor
por: Takada, Shinako, et al.
Publicado: (1990)

Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes
por: Spindelboeck, Walter, et al.
Publicado: (2016)

Functional binding of hexanucleotides to 3C protease of hepatitis A virus
por: Blaum, Bärbel S., et al.
Publicado: (2012)

Prisoners Treated for Hepatitis C with Protease Inhibitor, New York, USA, 2012
por: Moorjani, Harish, et al.
Publicado: (2015)

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
por: Teixeira, Rosângela, et al.
Publicado: (2013)

Nationwide Experience of Treatment with Protease Inhibitors in Chronic Hepatitis C Patients in Denmark: Identification of Viral Resistance Mutations
por: Sølund, Christina, et al.
Publicado: (2014)

Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations
por: de Wispelaere, Mélissanne, et al.
Publicado: (2019)

Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors
por: Hamed, Mahmoud, et al.
Publicado: (2021)

Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3
por: de Rozières, Sohela, et al.
Publicado: (2004)

Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments
por: Becker, Daniel, et al.
Publicado: (2016)

Treatment of hepatitis C virus infection in the future
por: Kanda, Tatsuo, et al.
Publicado: (2013)

Simeprevir for the treatment of hepatitis C virus infection
por: Izquierdo, Laure, et al.
Publicado: (2014)

The crystal structure of main protease from mouse hepatitis virus A59 in complex with an inhibitor
por: Cui, Wen, et al.
Publicado: (2019)

Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034
por: Madison, Vincent, et al.
Publicado: (2008)

Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034
por: Cheng, K.-C., et al.
Publicado: (2007)

Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant
por: Meewan, Ittipat, et al.
Publicado: (2019)

Simultaneous assay for protease activities of hepatitis C virus and human immunodeficiency virus based on fluorescence detection
por: Kabashima, Tsutomu, et al.
Publicado: (2019)

Naturally-occurring hepatitis C virus protease variants: implications for resistance to new antivirals
por: López-Labrador, F.X., et al.
Publicado: (2006)

Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors
por: Uddin, Reaz, et al.
Publicado: (2022)

The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease
por: Howe, Anita Y. M., et al.
Publicado: (2013)

Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran
por: Afrasiabi, Mozhgan, et al.
Publicado: (2015)

The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors
por: Nguyen, Linh Thuy, et al.
Publicado: (2016)

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study
por: Stahmeyer, Jona T., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ofo6qa95bt5t9c32b7r385vk72